相关实验视频

Updated: May 30, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

免疫检查点表达和在IDH1-突变和野生型质母细胞瘤的治疗影响

Avaniyapuram Kannan Murugan¹, Siddarth Kannan², Ali S Alzahrani³

¹Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh 11211 Saudi Arabia.

Current problems in cancer

|January 26, 2025

概括

编程细胞死亡蛋白1 (PDCD1) 和分化集群274 (CD274) 在质母细胞瘤中高度表达,无论IDH1突变状态如何. 这表明免疫疗法对质母细胞瘤患者有潜在的益处.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学遗传学是一个

背景情况:

编程细胞死亡蛋白1 (PDCD1) 和分化集群274 (CD274) 是瘤免疫逃避的关键调节者.
免疫检查点抑制剂具有治疗潜力,但它们在质母细胞瘤,特别是IDH1突变细胞瘤中的有效性尚不清楚.

研究的目的:

为了研究PDCD1和CD274在质母细胞瘤中的表达.
分析PDCD1/CD274表达和IDH1突变状态之间的关系.
探索这些因素对患者存活率的影响,并确定潜在的治疗点.

主要方法:

对两个独立的TCGA下一代测序 (NGS) 数据集 (n=577和n=153) 的分析.
使用cBioPortal进行突变分析,使用RNA测序进行表达分析,以及使用miRDB/miRabel进行miRNA分析.
进行了卡普兰-梅尔生存分析,以预测整体存活率.

主要成果:

在5.4%的质母细胞瘤中发现了IDH1突变,与改善的整体存活率 (OS) 相相关.
在IDH1-野生型和IDH1-突变型质母细胞瘤中,PDCD1和CD274显著过度表达,表达更高与较差的OS有关.
针对IDH1-野生型和IDH1-突变型瘤,确定了不同的基因和miRNA配置文件,突出显示PIK3R1和ITGB2是潜在的可用药物标.

结论:

无论IDH1突变状态如何,PDCD1和CD274在质母细胞瘤中都高度表达,这表明免疫治疗的潜力.
由于PIK3R1过度表达,IDH1-突变性质母细胞瘤可能受益于包括PI3K/AKT/mTOR抑制剂在内的联合治疗.

关键词:

在 AKT AKT 里面.CD274 是一个CD274 目标药物是药物目标.质母细胞瘤是一种质母细胞瘤.质瘤是一种质瘤.一个IDH1一个IDH1 免疫治疗是一种免疫疗法.突变突变是一种突变.在PD-1中使用PD-1.在PD-L1中.在 PDCD1 中,PDCD1 是在PI3K中,PI3K是指PI3K.这就是PIK3R1的原因.在mTOROR中使用mTOR.

更多相关视频

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.